Press releases
01 May 2022
|
15:03 PM CEST
BioMimics 3D®, a next generation biomimetic peripheral stent, now available nationwide with Veryan Medical and Premier collaboration
HORSHAM, UK – 01 MAY 2022 – Veryan Medical Inc. has been awarded a group purchasing agreement for Peripheral and Biliary Stents with Premier, Inc. Effective 01 May 2022, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the BioMimics 3D Vascular Stent System.
06 April 2021
|
17:14 PM CEST
Veryan Medical announces multimillion-euro investment in Galway operation
Galway, 06 April 2021 Veryan has announced a multimillion-euro investment at its Galway facility that will contribute to the further expansion and diversification of Veryan’s product portfolio beyond the BioMimics 3D Swirling Flow stent, marketed in Europe and USA to improve blood flow through arteries in the leg.
16 December 2020
|
16:28 PM CET
First patient enrolment in MIMICS 3D USA
Veryan Medical (Horsham, UK) is delighted to announce that the first patient was enrolled today in the MIMICS-3D USA study by John H. Rundback MD at NJ Endovascular & Amputation Prevention, NJ.
02 September 2020
|
19:02 PM CEST
First BioMimics 3D US Implant
Veryan Medical (Horsham, UK) has announced that Dr. Bret Wiechmann and his team at Vascular and Interventional Physicians in Gainesville, FL implanted the first commercial BioMimics 3D Vascular stent in the US, on the same day that the device was officially launched in the US. The BioMimics 3D self-expanding, nitinol stent features a highly differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up, MIMICS-2.
01 September 2020
|
10:43 AM CEST
BioMimics 3D US launch
Veryan Medical (Horsham, UK) today announced that it has launched the innovative BioMimics 3D Vascular Stent System in the US. The BioMimics 3D self-expanding, nitinol stent features a highly-differentiated, helical centre-line design that has achieved excellent clinical outcomes in clinical trials, including a pivotal study with 3-year follow-up.
10 August 2020
|
11:49 AM CEST
Veryan and Vasorum Joint Press Release- CELT ACD
Vasorum (Dublin, Ireland) and Veryan Medical (Horsham, UK) have announced that from today Veryan Medical will support Vasorum in the commercialisation of the Celt ACD in the USA. The Celt ACD is an Arterial Closure Device that has been used in more than 60,000 patients to date with excellent clinical results following percutaneous catheter-based vascular procedures.
09 June 2020
|
10:45 AM CEST
MIMICS-2 3-year data update
Professor Thomas Zeller (University Heart Centre Freiburg, Bad Krozingen, Germany) today presented the 36-month results from Veryan Medical’s MIMICS-2 study at CX 2020 Live.
13 December 2018
|
01:00 AM CET
01 June 2018
|
02:00 AM CEST
June 2018
Veryan Medical press release on completion of MIMICS 3D enrollment. 20th June 2018
01 February 2018
|
01:00 AM CET